Symbols / NRIX Stock $16.49 -1.14% Nurix Therapeutics, Inc.

Healthcare • Biotechnology • United States • NGM
NRIX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Arthur T. Sands M.D., Ph.D.
Exch · Country NGM · United States
Market Cap 1.71B
Enterprise Value 1.22B
Income -295.28M
Sales 71.78M
FCF (ttm) -145.46M
Book/sh 4.65
Cash/sh 5.23
Employees 317
Insider 10d —
IPO Jul 24, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -5.76
PEG —
P/S 23.76
P/B 3.55
P/C —
EV/EBITDA -3.98
EV/Sales 17.04
Quick Ratio 5.89
Current Ratio 6.01
Debt/Eq 12.20
LT Debt/Eq —
EPS (ttm) -3.17
EPS next Y -2.86
EPS Growth —
Revenue Growth -66.10%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-07-09
Earnings (prior) 2026-04-08
ROA -31.50%
ROE -61.40%
ROIC —
Gross Margin 0.00%
Oper. Margin -14.79%
Profit Margin 0.00%
Shs Outstand 103.41M
Shs Float 95.23M
Insider Own 1.10%
Instit Own 111.15%
Short Float 18.78%
Short Ratio 12.86
Short Interest 19.20M
52W High 22.50
vs 52W High -26.71%
52W Low 8.20
vs 52W Low 101.22%
Beta 1.98
Impl. Vol. 1.56%
Rel Volume 0.54
Avg Volume 1.10M
Volume 591.51K
Target (mean) $30.24
Tgt Median $30.00
Tgt Low $23.00
Tgt High $41.00
# Analysts 17
Recom Strong_buy
Prev Close $16.68
Price $16.49
Change -1.14%
About

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$30.24
Mean price target
2. Current target
$16.49
Latest analyst target
3. DCF / Fair value
$-25.32
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$16.49
Low
$23.00
High
$41.00
Mean
$30.24

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-27 reit HC Wainwright & Co. Buy → Buy $32
2026-04-23 reit Needham Buy → Buy $26
2026-04-10 reit HC Wainwright & Co. Buy → Buy $32
2026-04-09 main Wells Fargo Overweight → Overweight $28
2026-04-08 reit Needham Buy → Buy $26
2026-03-24 reit HC Wainwright & Co. Buy → Buy $32
2026-01-29 main Piper Sandler Overweight → Overweight $35
2026-01-29 main RBC Capital Outperform → Outperform $30
2026-01-29 main Stifel Buy → Buy $35
2026-01-29 main Wells Fargo Overweight → Overweight $29
2026-01-29 reit BTIG Buy → Buy $30
2026-01-29 main HC Wainwright & Co. Buy → Buy $32
2026-01-29 reit Needham Buy → Buy $26
2026-01-08 up Morgan Stanley Equal-Weight → Overweight $36
2025-12-16 main Wells Fargo Overweight → Overweight $30
2025-12-10 main Mizuho Outperform → Outperform $30
2025-12-10 main HC Wainwright & Co. Buy → Buy $31
2025-12-09 main BTIG Buy → Buy $30
2025-12-08 reit Needham Buy → Buy $26
2025-11-04 reit Needham Buy → Buy $26
News
RSS: Latest NRIX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-02 RING CHRISTINE Officer — 8,148 $15.24 $124,149
2026-03-02 RING CHRISTINE Officer — 8,148 $15.44 $125,793
2026-02-09 RING CHRISTINE Officer — 14,261 $16.66 $237,618
2026-02-03 HANSEN GWENN Officer — 31,333 $0.84 $26,320
2026-01-30 VAN HOUTE JOHANNES D Chief Financial Officer — 3,661 $16.58 $60,767
2026-01-30 VAN HOUTE JOHANNES D Chief Financial Officer — 11,496 — —
2026-01-30 HANSEN GWENN Officer — 4,895 $16.58 $81,249
2026-01-30 HANSEN GWENN Officer — 11,816 — —
2026-01-30 RING CHRISTINE Officer — 4,421 $16.58 $73,381
2026-01-30 RING CHRISTINE Officer — 10,534 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-11-30 2024-11-30 2023-11-30 2022-11-30
Total Revenue
83.98
+53.95%
54.55
-29.15%
76.99
+99.31%
38.63
Operating Revenue
83.98
+53.95%
54.55
-29.15%
76.99
+99.31%
38.63
Operating Expense
369.65
+38.15%
267.58
+15.31%
232.05
+4.29%
222.49
Research And Development
316.90
+42.99%
221.63
+17.17%
189.15
+2.52%
184.50
Selling General And Administration
52.74
+14.80%
45.94
+7.09%
42.90
+12.91%
38.00
General And Administrative Expense
52.74
+14.80%
45.94
+7.09%
42.90
+12.91%
38.00
Other Gand A
52.74
+14.80%
45.94
+7.09%
42.90
+12.91%
38.00
Total Expenses
369.65
+38.15%
267.58
+15.31%
232.05
+4.29%
222.49
Operating Income
-285.67
-34.10%
-213.03
-37.38%
-155.06
+15.67%
-183.87
Total Operating Income As Reported
-285.67
-34.10%
-213.03
-37.38%
-155.06
+15.67%
-183.87
EBITDA
-266.81
-35.71%
-196.60
-39.03%
-141.41
+18.29%
-173.06
Normalized EBITDA
-266.81
-35.71%
-196.60
-39.03%
-141.41
+18.29%
-173.06
Reconciled Depreciation
18.86
+14.78%
16.43
+20.32%
13.65
+26.33%
10.81
EBIT
-285.67
-34.10%
-213.03
-37.38%
-155.06
+15.67%
-183.87
Net Income
-264.46
-36.62%
-193.57
-34.47%
-143.95
+20.19%
-180.36
Pretax Income
-263.70
-36.42%
-193.30
-34.28%
-143.95
+20.19%
-180.36
Net Non Operating Interest Income Expense
21.97
+11.36%
19.73
+77.49%
11.12
+216.94%
3.51
Net Interest Income
21.97
+11.36%
19.73
+77.49%
11.12
+216.94%
3.51
Interest Income Non Operating
21.97
+11.36%
19.73
+77.49%
11.12
+216.94%
3.51
Interest Income
21.97
+11.36%
19.73
+77.49%
11.12
+216.94%
3.51
Tax Provision
0.76
+181.48%
0.27
0.00
0.00
Tax Rate For Calcs
0.00
-100.00%
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-264.46
-36.62%
-193.57
-34.47%
-143.95
+20.19%
-180.36
Net Income From Continuing Operation Net Minority Interest
-264.46
-36.62%
-193.57
-34.47%
-143.95
+20.19%
-180.36
Net Income From Continuing And Discontinued Operation
-264.46
-36.62%
-193.57
-34.47%
-143.95
+20.19%
-180.36
Net Income Continuous Operations
-264.46
-36.62%
-193.57
-34.47%
-143.95
+20.19%
-180.36
Normalized Income
-264.46
-36.62%
-193.57
-34.47%
-143.95
+20.19%
-180.36
Net Income Common Stockholders
-264.46
-36.62%
-193.57
-34.47%
-143.95
+20.19%
-180.36
Diluted EPS
—
-2.88
-8.68%
-2.65
+28.57%
-3.71
Basic EPS
—
-2.88
-8.68%
-2.65
+28.57%
-3.71
Basic Average Shares
—
67.12
+23.52%
54.34
+11.79%
48.61
Diluted Average Shares
—
67.12
+23.52%
54.34
+11.79%
48.61
Diluted NI Availto Com Stockholders
-264.46
-36.62%
-193.57
-34.47%
-143.95
+20.19%
-180.36
Line Item Trend 2025-11-30 2024-11-30 2023-11-30 2022-11-30
Total Assets
688.13
+2.81%
669.34
+88.23%
355.60
-14.68%
416.76
Current Assets
606.82
-2.03%
619.39
+109.60%
295.50
-7.21%
318.45
Cash Cash Equivalents And Short Term Investments
592.94
-2.73%
609.58
+111.73%
287.91
-6.87%
309.14
Cash And Cash Equivalents
246.96
+124.52%
110.00
+101.36%
54.63
-15.27%
64.47
Other Short Term Investments
345.98
-30.75%
499.59
+114.16%
233.28
-4.65%
244.67
Receivables
—
—
—
0.00
Accounts Receivable
—
—
—
0.00
Taxes Receivable
—
—
—
0.00
Prepaid Assets
—
—
—
—
Other Current Assets
13.88
+41.55%
9.80
+29.08%
7.59
-18.40%
9.31
Total Non Current Assets
81.32
+62.78%
49.96
-16.87%
60.09
-38.87%
98.31
Net PPE
73.01
+59.07%
45.90
-4.28%
47.95
+62.50%
29.51
Gross PPE
110.79
+37.80%
80.40
+8.35%
74.20
+50.88%
49.18
Accumulated Depreciation
-37.78
-9.51%
-34.50
-31.44%
-26.25
-33.45%
-19.67
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
7.19
-5.30%
7.59
+8.55%
6.99
+18.01%
5.93
Construction In Progress
0.14
-71.63%
0.50
-15.33%
0.59
-15.78%
0.70
Other Properties
94.09
+40.08%
67.17
+5.98%
63.38
+63.65%
38.73
Leases
9.37
+82.28%
5.14
+58.74%
3.24
-15.35%
3.83
Investments And Advances
—
0.00
-100.00%
7.42
-88.38%
63.88
Other Non Current Assets
8.31
+104.66%
4.06
-14.06%
4.72
-4.04%
4.92
Total Liabilities Net Minority Interest
149.39
+4.94%
142.35
-8.22%
155.10
+37.18%
113.06
Current Liabilities
86.47
-9.79%
95.85
+10.23%
86.96
+23.07%
70.66
Payables And Accrued Expenses
42.43
+38.80%
30.57
+99.58%
15.32
+19.43%
12.82
Payables
12.27
-3.50%
12.72
+97.78%
6.43
+24.90%
5.15
Accounts Payable
11.21
-2.33%
11.48
+79.38%
6.40
+26.40%
5.06
Current Accrued Expenses
30.16
+68.93%
17.85
+100.89%
8.89
+15.76%
7.68
Pensionand Other Post Retirement Benefit Plans Current
21.54
+29.52%
16.63
+8.68%
15.30
+16.25%
13.16
Total Tax Payable
1.06
-14.39%
1.24
+4023.33%
0.03
-64.71%
0.09
Current Debt And Capital Lease Obligation
2.82
-64.76%
8.01
+7.01%
7.49
+35.42%
5.53
Current Capital Lease Obligation
2.82
-64.76%
8.01
+7.01%
7.49
+35.42%
5.53
Current Deferred Liabilities
17.58
-54.18%
38.36
-20.24%
48.10
+27.81%
37.63
Current Deferred Revenue
17.58
-54.18%
38.36
-20.24%
48.10
+27.81%
37.63
Other Current Liabilities
2.10
-7.87%
2.27
+202.93%
0.75
-50.03%
1.50
Total Non Current Liabilities Net Minority Interest
62.92
+35.32%
46.50
-31.77%
68.15
+60.69%
42.41
Long Term Debt And Capital Lease Obligation
52.91
+160.76%
20.29
-12.26%
23.12
+259.42%
6.43
Long Term Capital Lease Obligation
52.91
+160.76%
20.29
-12.26%
23.12
+259.42%
6.43
Non Current Deferred Liabilities
10.01
-61.80%
26.21
-41.79%
45.02
+25.15%
35.97
Non Current Deferred Revenue
10.01
-61.80%
26.21
-41.79%
45.02
+25.15%
35.97
Stockholders Equity
538.75
+2.23%
526.99
+162.85%
200.49
-33.98%
303.70
Common Stock Equity
538.75
+2.23%
526.99
+162.85%
200.49
-33.98%
303.70
Capital Stock
0.10
+34.21%
0.08
+55.10%
0.05
+4.26%
0.05
Common Stock
0.10
+34.21%
0.08
+55.10%
0.05
+4.26%
0.05
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
101.81
+34.19%
75.87
+55.73%
48.72
+3.28%
47.17
Ordinary Shares Number
101.81
+34.19%
75.87
+55.73%
48.72
+3.28%
47.17
Additional Paid In Capital
1,541.77
+21.83%
1,265.54
+69.57%
746.30
+5.23%
709.22
Retained Earnings
-1,003.23
-35.80%
-738.77
-35.50%
-545.20
-35.87%
-401.25
Gains Losses Not Affecting Retained Earnings
0.10
-30.00%
0.15
+122.90%
-0.66
+84.83%
-4.32
Other Equity Adjustments
0.10
-30.00%
0.15
+122.90%
-0.66
+84.83%
-4.32
Total Equity Gross Minority Interest
538.75
+2.23%
526.99
+162.85%
200.49
-33.98%
303.70
Total Capitalization
538.75
+2.23%
526.99
+162.85%
200.49
-33.98%
303.70
Working Capital
520.35
-0.61%
523.53
+151.04%
208.54
-15.84%
247.79
Invested Capital
538.75
+2.23%
526.99
+162.85%
200.49
-33.98%
303.70
Total Debt
55.73
+96.90%
28.30
-7.55%
30.61
+155.88%
11.96
Capital Lease Obligations
55.73
+96.90%
28.30
-7.55%
30.61
+155.88%
11.96
Net Tangible Assets
538.75
+2.23%
526.99
+162.85%
200.49
-33.98%
303.70
Tangible Book Value
538.75
+2.23%
526.99
+162.85%
200.49
-33.98%
303.70
Available For Sale Securities
—
—
7.42
-88.38%
63.88
Investmentin Financial Assets
—
0.00
-100.00%
7.42
-88.38%
63.88
Line Item Trend 2025-11-30 2024-11-30 2023-11-30 2022-11-30
Operating Cash Flow
-249.47
-44.55%
-172.58
-112.11%
-81.36
+49.09%
-159.81
Cash Flow From Continuing Operating Activities
-249.47
-44.55%
-172.58
-112.11%
-81.36
+49.09%
-159.81
Net Income From Continuing Operations
-264.46
-36.62%
-193.57
-34.47%
-143.95
+20.19%
-180.36
Depreciation Amortization Depletion
18.86
+14.78%
16.43
+20.32%
13.65
+26.33%
10.81
Depreciation
18.86
+14.78%
16.43
+20.32%
13.65
+26.33%
10.81
Depreciation And Amortization
18.86
+14.78%
16.43
+20.32%
13.65
+26.33%
10.81
Other Non Cash Items
—
0.29
—
0.20
Stock Based Compensation
37.97
+11.90%
33.93
+0.76%
33.67
+19.70%
28.13
Operating Gains Losses
0.09
+187.10%
0.03
-94.42%
0.56
+6077.78%
0.01
Gain Loss On Sale Of PPE
0.09
+187.10%
0.03
-94.42%
0.56
+6077.78%
0.01
Change In Working Capital
-31.60
-71.71%
-18.40
-191.45%
20.12
+205.78%
-19.02
Change In Receivables
—
0.00
0.00
-100.00%
6.00
Changes In Account Receivables
—
0.00
0.00
-100.00%
6.00
Change In Prepaid Assets
-6.23
-1257.08%
-0.46
-121.46%
2.14
+295.52%
-1.09
Change In Payables And Accrued Expense
16.68
-2.03%
17.02
+259.40%
4.74
-37.42%
7.57
Change In Accrued Expense
17.31
+46.50%
11.82
+278.35%
3.12
-58.28%
7.49
Change In Payable
-0.63
-112.09%
5.21
+222.74%
1.61
+1798.82%
0.09
Change In Account Payable
-0.63
-112.09%
5.21
+222.74%
1.61
+1798.82%
0.09
Change In Other Working Capital
-36.98
-29.53%
-28.55
-246.31%
19.51
+173.28%
-26.63
Change In Other Current Liabilities
-5.07
+21.05%
-6.42
-2.39%
-6.27
-28.68%
-4.87
Investing Cash Flow
147.85
+157.37%
-257.71
-477.32%
68.30
+151.13%
27.20
Cash Flow From Continuing Investing Activities
147.85
+157.37%
-257.71
-477.32%
68.30
+151.13%
27.20
Net PPE Purchase And Sale
-14.00
-51.00%
-9.27
-10.38%
-8.40
+31.39%
-12.24
Purchase Of PPE
-14.00
-51.00%
-9.27
-10.38%
-8.40
+31.39%
-12.24
Capital Expenditure
-14.00
-51.00%
-9.27
-10.38%
-8.40
+31.39%
-12.24
Net Investment Purchase And Sale
161.85
+165.15%
-248.44
-423.90%
76.70
+94.47%
39.44
Purchase Of Investment
-455.69
+35.63%
-707.95
-187.40%
-246.33
-2.91%
-239.37
Sale Of Investment
617.54
+34.39%
459.51
+42.25%
323.04
+15.86%
278.81
Financing Cash Flow
238.64
-50.86%
485.67
+14996.89%
3.22
-97.25%
117.19
Cash Flow From Continuing Financing Activities
238.64
-50.86%
485.67
+14996.89%
3.22
-97.25%
117.19
Net Common Stock Issuance
234.76
-50.94%
478.50
0.00
-100.00%
114.16
Proceeds From Stock Option Exercised
3.88
-45.90%
7.17
+122.94%
3.22
+6.07%
3.03
Changes In Cash
137.03
+147.48%
55.37
+662.30%
-9.85
+36.13%
-15.42
Beginning Cash Position
110.90
+99.72%
55.53
-15.06%
65.38
-19.08%
80.79
End Cash Position
247.93
+123.56%
110.90
+99.72%
55.53
-15.06%
65.38
Free Cash Flow
-263.47
-44.88%
-181.86
-102.59%
-89.77
+47.83%
-172.05
Income Tax Paid Supplemental Data
—
—
—
0.00
Amortization Of Securities
-10.32
+8.56%
-11.29
-108.23%
-5.42
-1372.54%
0.43
Common Stock Issuance
234.76
-50.94%
478.50
0.00
-100.00%
114.16
Issuance Of Capital Stock
234.76
-50.94%
478.50
0.00
-100.00%
114.16
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category